0001396814-24-000084.txt : 20240613 0001396814-24-000084.hdr.sgml : 20240613 20240613181503 ACCESSION NUMBER: 0001396814-24-000084 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240611 FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLONIN JONATHAN CENTRAL INDEX KEY: 0001875723 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 241042486 MAIL ADDRESS: STREET 1: C/O PACIRA BIOSCIENCES, INC. STREET 2: 5401 WEST KENNEDY BOULEVARD, SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 BUSINESS PHONE: 813-553-6680 MAIL ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 wk-form4_1718316890.xml FORM 4 X0508 4 2024-06-11 0 0001396814 Pacira BioSciences, Inc. PCRX 0001875723 SLONIN JONATHAN C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890 TAMPA FL 33609 0 1 0 0 Chief Medical Officer 1 Common Stock 2024-06-11 2024-06-11 4 S 0 5012 28.57 D 44569.475 D Common Stock 2024-06-12 4 A 0 54300 0 A 98869.475 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. /s/ Kristen Williams, Attorney-in-Fact 2024-06-13